Economic evaluation of cholesterol-related interventions in general practice. An appraisal of the evidence

Journal of Epidemiology and Community Health

Volumn 52, Issue 9, 1998, Pages 586-594

  Van Der Weijden, Trudy ^a   Knottnerus, J André ^a   Ament, André J H A ^a   Stoffers, Henri E J H ^a   Grol, Richard P T M ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; COLESTIPOL; COLESTYRAMINE; FLUINDOSTATIN; GEMFIBROZIL; HYPOCHOLESTEROLEMIC AGENT; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; STATINE;

ARTICLE; COMMUNITY MEDICINE; COST EFFECTIVENESS ANALYSIS; DIET THERAPY; DRUG COST; ECONOMIC EVALUATION; GENERAL PRACTICE; HEALTH PROMOTION; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; QUALITY ADJUSTED LIFE YEAR;

EID: 0031669802     PISSN: 0143005X     EISSN: None     Source Type: Journal    
DOI: 10.1136/jech.52.9.586     Document Type: Article

References (114)

1. Davidoff F. Evangelists and snails redux: the case of cholesterol screening. Ann Intern Med 1996;124:513-14.
2. Detsky AS, Naglie IG. A clinician's guide to cost-effectiveness analysis. Ann Intern Med 1990;113:147-54.
3. Tugwell P, Bennett KJ, Sackett DL, Haynes RB. The measurement iterative loop: A framework for the critical appraisal of need, benefits and costs of health interventions. J Chron Dis 1985;38:339-51.
4. Drummond MF, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press, 1987.
5. O'Brien B, Rushby J. Outcome assessment in cardiovascular cost-benefit studies. Am Heart J 1990;119:740-8.
6. Maynard A. The design of future cost-benefit studies. Am Heart J 1990;119;761-5.
7. Luce BR, Elixhauser A. Estimating costs in the economic evaluation of medical technologies. Int J Technol Assess Health Care 1990;6:57-75.
8. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB, for the Panel on Cost-Effectiveness in Health and Medicine. Recommendations of the Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996;276: 1253-8.
9. Goldman L, Gordon DJ, Rifkind BM, et al. Cost and health implications of cholesterol lowering. Circulation 1992;85: 1960-8.
10. Kupersmith J, Holmes-Rovner M, Hogan A, Rovner D, Gardiner J. Cost-effectiveness analysis in heart disease, Part II: Preventive therapies. Progr Cardiovasc Dis 1995;37: 243-71.
11. Chrisp P. Simvastatin in hypercholesterolaemia. Pharmacoeconomics 1992;1:124-45.
12. Tengs TO, Adams ME, Pliskin JS, et al. Five-hundred life-saving-interventions and their cost-effectiveness. Risk Analysis 1995;15:369-90.
13. Baltussen R, Ament A, Leidl R. Making cost assessments based on RCTs more useful to decision-makers. Health Policy 1996;37:163-83.
14. Beurden E van, James R, Montague D, Christian J, Dunn T. Community-based cholesterol screening and education to prevent heart disease: five-year results of the North Coast Cholesterol Check Campaign. Aust J Public Health 1993;17:109-16.
15. Mäenpää H, Manninen V, Heinonen OP. Compliance with medication in the Helsinki Heart Study. Eur J Clin Pharmacol 1992;42:15-19.
16. Shepherd J, Cobbe SM, Ford I, et al for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
17. Andrade SE, Walker AM, Gottlieb LK, et al. Discontinuation of antihyperlipidemic drugs. Do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med 1995;332:1125-31.
18. Rand CS. Measuring adherence with therapy for chronic diseases: implications for the treatment of heterozygous familial hypercholesterolemia. Am J Cardiol 1993;72:68-74D.
19. Elixhauser A, Luce BR, Taylor WR, Reblando J. Health care CBA/CEA: An update on the growth and composition of the literature. Med Care 1993;31 (suppl 31):JS1-11.
20. Shephard DS, Thompson MS. First principles of cost-effectiveness analysis in health. Public Health Rep 1979;94: 535-43.
21. Guyatt G, Drummond M, Feeny D, Haynes RB, Tugwell P. Guidelines for health technology assessment: therapeutic technologies. In: Feeny D, Guyatt G, Tugwell P, eds. Health care technology. Effectiveness, efficiency and public policy. Montreal: The Institute for Research on Public Policy, 1986.
22. Udvarhelyi S, Colditz GA, Rai A, Epstein AM. Cost-effectiveness and cost-benefit analyses in the medical literature. Ann Intern Med 1992;116:238-44.
23. Drummond M, Brandt A, Luce B, Rovira J. Standardizing methodologies for economic evaluation in health care. Practice, problems, and potential. Int J Technol Assess Health Care 1993;9:26-36.
24. Drummond MF, Jefferson TO, the BMJ Economic Evaluation Working Party. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ 1996; 313:275-83.
25. Berwick DM, Cretin S, Keeler E. Cholesterol, children, and heart disease: an analysis of alternatives. Pediatrics 1981;68: 721-30.
26. Korman L, Borysiuk L. Replacing lovastatin with pravastatin: effect on serum lipids and costs. Am J Health Syst Pharm 1995;52:1078-82.
27. Pedersen TR, Kjekshus J, Berg K, et al; for the Scandinavian Simvastatin Survival Study Group. Cholesterol lowering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival Study. Circulation 1996;93: 1796-802.
28. Johannesson M, Borgquist L, Nilsson-Ehle P, Jönsson B, Ekbom T, Lindholm L. The cost of screening for hypercholesterolemia - Results form a clinical trial in Swedish primary health care. Scand J Clin Lab Invest 1993; 53:725-32.
29. Hofer T, Weissfeld J. Designing a simpler high blood cholesterol case detection strategy: are the advantages of the NCEP protocol worth the complexity? Med Decis Making 1994;14:357-68.
30. Garber AM, Littenberg B, Sox HC, Wagner JL, Gluck M. Costs and health consequences of cholesterol screening for asymptomatic older Americans. Arch Intern Med 1991;151: 1089-95.
31. Heudebert GR, Van Ruiswyk J, Hiatt J, Schectman G. Combination drug therapy for hypercholesterolemia. Arch Intern Med 1993;153:1828-37.
32. Grover SA, Coupal L, Fahkry R, Suissa S. Screening for hypercholesterolemia among Canadians: How much will it cost? Can Med Assoc J 1991;144:161-8.
33. Eddy DM. Rationing resources while improving quality. How to get more for less. JAMA 1994;272:817-24.
34. Bloom BS. Medical management and managing medical care: The dilemma of evaluating new technology. Am Heart J 1990;119:754-61.
35. Lindholm L, Rosén M, Weinehall L, Asplund K. Cost effectiveness and equity of a community based cardiovascular disease prevention programme in Norsjö, Sweden. J Epidemiol Community Health 1996;50:190-5.
36. Hall JP, Heller RF, Dobson AJ, Lloyd DM, Sanson-Fisher RW, Leeder SR. A cost-effectiveness analysis of alternative strategies for the prevention of heart disease. Med J Aust 1988;148:273-7.
37. Langham S, Thorogood M, Normand C, Muir J, Jones L, Fowler G. Costs and cost-effectiveness of health checks conducted by nurses in primary care: the Oxcheck study. BMJ 1996;312:1265-8.
38. Wonderling D, McDermott C, Buxton M, et al. Costs and cost-effectiveness of cardiovascular screening and intervention: the British family heart study. BMJ 1996;312: 1269-73.
39. Wonderling D, Langham S, Buxton M, Normand C, McDermott C. What can be concluded from the Oxcheck and British family heart studies on cost-effectiveness analyses. BMJ 1996;312:1274-8.
40. O'Neill C, Normand C, Cupples M, McKnight A. Cost effectiveness of personal health education in primary care for people with angina in the Greater Belfast area of Northern Ireland. J Epidemiol Community Health 1996;50: 538-10.
41. Yusuf S, Anand S. Cost of prevention. The case of lipid lowering. Circulation 1996;93:1774-6.
42. Drummond MF, Heyse J, Cook J, McGuire A. Selection of end points in economic evaluations of coronary-heart-disease interventions. Med Decis Making 1993;13: 184-90.
43. Hogan T. Health and economic issues in the prevention of coronary heart disease. Am J Cardiol 1995;76:140-2A.
44. Chrisp P, Lewis NJW, Milne RJ. Simvastatin: a pharmacoeconomic evaluation of its cost-effectiveness in hypercholesterolaemia and prevention of coronary heart disease. PharmacoEconomics 1992;1:124-45.
45. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study. Lancet 1994;344:1383-9.
46. Strachan D, Rose G. Strategies of prevention revisited: effects of imprecise measurement of risk factors on the evaluation of "high-risk" and "population-based" approaches to prevention of cardiovascular disease. J Clin Epidemiol 1991;44:1187-96.
47. Forrow L, Calkins DR, Allshouse K, Horowitz G, Delbanco TL. Evaluating cholesterol screening. The importance of controlling for regression to the mean. Arch Intern Med 1995;155:2177-84.
48. Weissfeld JL, Holloway JJ. Precision of blood cholesterol measurement and high blood cholesterol case-finding and treatment. J Clin Epidemiol 1992;45:971-84.
49. Martens LL. Effect of biological and analytical variation in cholesterol measurement on the cost-effectiveness of cholesterol-lowering therapy. PharmacoEconomics 1992;2: 414-21.
50. Imperial Cancer Research Fund OXCHECK Study Group. Prevalence of risk factors for heart disease in OXCHECK trial: implications for screening in primary care. BMJ 1991;302:1057-60.
51. Silagy C, Mant D, Carpenter L, Muir J, Neil A. Modelling different strategies to prevent coronary heart disease in primary care. J Clin Epidemiol 1994;47:993-1001.
52. Robertson M. Costs in general practice. [Letter]. BMJ 1996;313:1143-4.
53. Krahn M, Naylor D, Basinski AS, Detsky AS. Comparison of an aggressive (U.S.) and a less aggressive (Canadian) policy for cholesterol screening and treatment. Ann Intern Med 1991;115:248-55.
54. Havas S, Reisman J, Hsu L, et al. Does cholesterol screening result in negative labeling effects? Results of the Massachusetts Model System for Blood Cholesterol Screening Project. Arch Intern Med 1991;151:113-19.
55. Christensen B. Psychological reactions to information about risk of ischaemic heart disease in general practice. Scand J Prim Health Care 1995;13:164-7.
56. Brett AS. Psychologic effects of the diagnosis and treatment of hypercholesterolemia: lessons from case studies. Am J Med 1991;91:642-7.
57. Lefebvre RC, Hursey KG, Carleton RA. Labeling of participants in high blood pressure screening programmes. Implications for blood cholesterol screenings. Arch Intern Med 1988;148:1993-7.
58. MacDonald LA, Sackett DL, Haynes RB, et al. Labelling in hypertension: a review of the behavioral and psychological consequences. J Chron Dis 1984;37:933-42.
59. Råstam L, frick JO, Gullberg B. Work absenteeism in men who are labelled hypercholesterolaemic at screening. Eur Heart J 1991;12:1316-20.
60. Stoate HG. Can health screening damage your health? J R Coll Gen Pract 1989;39:193-5.
61. Fisher PM, Guinan KH, Burke JJ, Karp WB, Richards JW jr. Impact of a public cholesterol screening program. Arch Intern Med 1990;150:2567-72.
62. Thorell B, Svärdsudd K. Intervention against ischaemic heart disease risk factors in primary health care in a semi-rural community. The population study "50-year-old people in Kungsör". Scand J Prim Health Care 1994;12:51-6.
63. Fox GN. Cholesterol: truth in labelling. Fam Pract Res J 1991;11:241-5.
64. Kinlay S, Heller RF. Effectiveness and hazards of case finding for a high cholesterol concentration. BMJ 1990;300: 1545-7.
65. Tijmstra T. The psychological and social implications of serum cholesterol screening. International Journal of Risk Safety in Medicine 1990;1:29-44.
66. Rose G, Heller RF, Tunstall Pedoe H, Christie DGS. Heart disease prevention project: a randomised controlled trial in industry. BMJ 1989;1:747-51.
67. Feldman W. How serious are the adverse effects of screening? J Gen Intern Med 1990;5 (suppl 5):S50-3.
68. Stewart-Brown S, Farmer A. Screening could seriously damage your health. Decisions to screen must take account of the social and psychological costs. BMJ 1997;314:533-4.
69. Roeback JR, Cook JR, Guess HA, Heyse JF. Time-dependent variability in repeated measurements of cholesterol levels: clinical implications for risk misclassification and intervention monitoring. J Clin Epidemiol 1993;46: 1159-71.
70. Kent Kwoh C. Cost studies: caveats to the reader. J Clin Epidemiol 1988;41:211-13.
71. Russell LB, Gold MR, Siegel JE, et al for the Panel on Cost-Effectiveness in Health and Medicine. The role of cost-effectiveness analysis in health and medicine. JAMA 1996;276:1172-7.
72. Schulman KA, Kinosian B, Jacobson TA, et al. Reducing high blood cholesterol levels with drugs. Cost-effectiveness of pharmacologic management. JAMA 1990;264:3025-33.
73. Lim MCL, Foo WM. Efficacy and cost-effectiveness of simvastatin and gemfibrozil in the treatment of hyperlipidaemia. Ann Acad Med 1992;21:34-7.
74. Blum CB. Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase [published erratum appears in Am J Cardiol 1994;74:639]. Am J Cardiol 1994;73:3-11D.
75. Smart AJ, Walters L. Pharmaco-economic assessment of the HMG-CoA reductase inhibitors. S Afr Med J 1994;84: 834-7.
76. Schrott HG, Stein EA, Dujovne CA, et al. Enhanced low-density lipoprotein cholesterol reduction and cost-effectiveness by low-dose colestipol plus lovastatin combination therapy. Am J Cardiol 1995;75:34-9.
77. Oster G, Borok GM, Menzin J, et al. Cholesterol-reduction intervention study (CRIS): a randomized trial to assess effectiveness and costs in clinical practice. Arch Intern Med 1996;156:731-9.
78. Oster G, Borok GM, Menzin J, et al. A randomized trial to assess effectiveness and cost in clinical practice: rationale and design of the Cholesterol Reduction Intervention Study (CRIS). Control Clin Trials 1995;16:3-16.
79. Himmelstein DU, Woolhandler S. Free care, cholestyramine, and health policy. N Engl J Med 1984;311:1511-14.
80. Weinstein MC, Stason WB. Cost-effectiveness of interventions to prevent or treat coronary heart disease. Ann Rev Public Health 1985;6:41-63.
81. Stason WB. Costs and benefits of risk factor reduction for coronary heart disease: Insights from screening and treatment of serum cholesterol. Am Heart J 1990;119:718-24.
82. Oster G, Epstein A. Cost-effectiveness of antihyperlipemic therapy in the prevention of coronary heart disease. The case of cholestyramine. JAMA 1987;258:2381-7.
83. Kinosian BP, Eisenberg J. Cutting into cholesterol. Cost-effective alternatives for treating hypercholesterolemia. JAMA 1988;259:2249-54.
84. Martens LL, Rutten FFH, Erkelens DW, et al. Clinical benefits and cot-effectiveness of lowering serum cholesterol levels: The case of simvastatin and cholestyramine in the Netherlands. Am J Cardiol 1990;65:27-32F.
85. Martens LL, Rutten FH, Erkelens DW, et al. Cost effectiveness of cholesterol-lowering therapy in the Netherlands. Simvastatin versus cholestyramine. Am J Med 1989;87 (suppl 4A):54-8S.
86. Sarma S, Fifer SK. Gemfibrozil cost-benefit study. Targeting subgroups for effective hyperlipidaemia drug therapy. Drugs 1990;40 (suppl 1):42-52.
87. Hay JW, Wittels EH, Gotto AM. An economic evaluation of lovastatin for cholesterol lowering and coronary artery disease reduction. Am J Cardiol 1991;67:789-96.
88. Goldman L, Weinstein MC, Goldman PA, et al. Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease. JAMA 1991;265:1145-51.
89. Click H, Heyse JF, Thompson D, et al. A model for evaluating the cost-effectiveness of cholesterol-lowering treatment. Int J Technol Assess Health Care 1992;8:719-34.
90. Hjalte K, Lindgren B, Persson U. Cost-effectiveness of simvastatin versus cholestyramine. Results for Sweden. PharmacoEconomics 1992;1:213-16.
91. Guibert R, Contandriopoulos AP, Champagne F, et al. Cost-effectiveness analysis of lipid modulators in Canada: Results and potential usefulness. Can J Cardiol 1993;9 (suppl):28-9D.
92. Goldman L, Goldman PA, Williams LW, et al. Cost-effectiveness considerations in the treatment of heterozygous familial hypercholesterolaemia with medications. Am J Cardiol 1993;72:75-9D.
93. Martens LL, Guibert R. Cost-effectiveness analysis of lipid-modifying therapy in Canada: comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease. Clin Ther 1994;16:1052-62.
94. Hamilton VH, Racicot FE, Zowall H, et al. The cost-effectiveness of HMG-coA reductase inhibitors to prevent coronary heart disease. JAMA 1995;273:1032-8.
95. Pharoah PDP, Hollingworth W. Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: life table method applied to health authority population. BMJ 1996; 312:1443-8.
96. Ashraf T, Hay JW, Pitt B, et al. Cost-effectiveness of pravastatin in secondary prevention of coronary artery diesease. Am J Cardiol 1996;78:409-14.
97. Jönsson B, Johannesson M, Kjekshus J, et al, for the Scandinavian Simvastatin Survival Study Group. Cost-effectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study (4S). Eur Heart J 1996;17:1001-7.
98. Johannesson M, Jönsson B, Kjeksus J, et al, for the Scandinavian Simvastatin Survival Study Group. Cost effectiveness of Simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. N Engl J Med 1997;336:332-6.
99. Oster G, Epstein AM. Primary prevention and coronary heart disease: The economic benefits of lowering serum cholesterol. Am J Public Health 1986;76:647-56.
100. Wilson MG, Edmunson J, DeJoy DM. Cost effectiveness of work-site cholesterol screening and intervention programs. J Occup Med 1992;34:642-9.
101. Tomson Y, Johannesson M, Åberg H. The costs and effects of two different lipid intervention programmes in primary health care. J Intern Med 1995;237:13-17.
102. McGehee MM, Johnson EQ, Rasmussen HM, et al. Benefits and costs of medical nutrition therapy by registered dietitians for patients with hypercholesterolemia. Massachusetts Dietetic Association. J Am Diet Assoc 1995; 95:1041-3.
103. Kelley MD. Hypercholesterolemia: the cost of treatment in perspective. South Med J 1990;83:1421-5.
104. Reckless JPD. The economics of cholesterol lowering. Baillieres Clin Endocrinol Metab 1990;4:947-72.
105. Reckless JPD. Cost-effectiveness of hypolipidaemic drugs. Postgrad Med J 1993;69 (suppl 1):S30-3.
106. Assmann G, Schulte H. Primary prevention of coronary heart disease in the Federal Republic of Germany. Analysis of cost-effectiveness. Drugs 1990;40 (suppl 1):33-7.
107. Kristiansen IS, Eggen AE, Thelle DS. Cost effectiveness of incremental programmes for lowering serum cholesterol concentration: is individual intervention worth while? BMJ 1991;302:1119-22.
108. Weissfeld JL, Holloway JJ. Precision of blood cholesterol measurement and high blood cholesterol case-finding and treatment. J Clin Epidemiol 1992;45:971-84.
109. Weissfeld JL, Weissfeld LA, Holloway JJ, et al. A mathematical representation of the Expert Panel's Guide for high blood cholesterol case-finding and treatment. Med Decis Making 1990;10:135-46.
110. Kinlay S, O'Connell D, Evans D, et al. A new method for estimating cost effectiveness of cholesterol reduction therapy for prevention of heart disease. PharmacoEconomics 1994;5:238-18.
111. Field K, Thorogood M, Silagy C, et al. Strategies for reducing coronary risk factors in primary care: which is most cost effective? [see comments]. BMJ 1995;310:1109-12.
112. Johannesson M, Borquist L, Jönsson B, et al, for the CELL Study Group. The cost effectiveness of lipid lowering in Swedish primary health care. J Intern Med 1996;240:23-9.
113. Stinnett AA, Mittleman MA, Weinstein MC, et al. Apendix C: The cost-effectiveness of dietary and pharmacological therapy for cholesterol reduction in adults. In: Gold MR, Siegel JE, Russell LB, et al, eds. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996: 349-91.
114. Plans Rubio P. Cost-effectiveness of dietary treatment of hypercholesterolemia in Spain. Public Health 1997;111:33-40.